Evidence map›Paper›PMID 40620795›Full record

Trial reportFrontiers in endocrinology2025

The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy.

Deyue Kong, Ziyang Shen, Lanlan Jiang, Xiaojing Xie, Rengna Yan, Ting Jing, Yun Hu, Jianhua Ma

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04847219 (Efficacy and Safety of Premixed Insulin Treatment in Patients With Type 2 Diabetes Mellitus Observed by Different Type of Flash Glucose Mornitoring), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04847219 nacompletednot on this map

Efficacy and Safety of Premixed Insulin Treatment in Patients With Type 2 Diabetes Mellitus Observed by Different Type of Flash Glucose Mornitoring

TypeinterventionalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2019 to 2021Enrolled239ConditionsType 2 DiabetesArmsProfessional flash glucose mornitoring, Personal flash glucose mornitoring
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deyue Kong *Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ziyang Shen *Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Lanlan JiangDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaojing XieDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Rengna YanDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ting JingDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yun HuDepartment of Endocrinology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
Jianhua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Patients on premixed insulin therapy usually have poor glycemic control. This study aimed to investigate the effect of vildagliptin in these patients. Methods: This real-world study included patients with type 2 diabetes mellitus (T2DM), who were poorly glycemic controlled on premixed insulin therapy and were subsequently added vildagliptin. The control group consisted of patients who only had their insulin doses adjusted without adding vildagliptin, matched for age, diabetic duration, HbA1c, and BMI. All patients underwent FGM, glycated hemoglobin(HbA1c), and glycated albumin(GA) measurements at baseline and three months after the treatment adjustment. Results: Patients receiving vildagliptin treatment demonstrated significant reductions in HbA1c and GA levels (P<0.001 and P=0.009, respectively). The vildagliptin group exhibited a remarkable decrease in the mean amplitude of glycemic excursion (MAGE) (8.58 ± 0.36 Conclusion: Vildagliptin added to premixed insulin effectively lowers blood glucose levels and reduces glycemic variability in patients with type 2 diabetes mellitus. Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04847219.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Hypoglycemic AgentsInsulinVildagliptinAgedFemaleGlycated HemoglobinGlycated Serum AlbuminGlycemic ControlHumansMaleMiddle AgedBlood GlucoseGlycated HemoglobinGlycated Serum Albuminhemoglobin A1c protein, humanHypoglycemic AgentsInsulinVildagliptinflash glucose monitoringglycemic excursionpremixed insulintype 2 diabetes mellitusvildagliptin

Identifiers

PMID40620795
PMCPMC12226302

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.